A Study of the Ulthera® System for the Treatment of Axillary Hyperhidrosis

Status Terminated

Clinical Trial Summary

This is a prospective, multi-center, randomized, double-blinded study. Subjects enrolled will be randomly assigned to receive either active treatments for axillary hyperhidrosis with the Ulthera System in both axillas, or sham treatments, also with the Ulthera System but with the energy settings on the device set to deliver no ultrasound energy. Subjects will be randomized in a 2:1 ratio, with 2 subjects randomized to active treatment for every one subject randomized to sham treatment. Subjects will receive 2 study treatments 30 days apart.

Subjects and study personnel conducting efficacy measures will be blinded to the assigned treatment groups. The study hypothesis is that subjects in the active treatment group will have a greater reduction in underarm sweating compared to those in the sham group as measured by a quality of life questionnaire.

All subjects will undergo follow-up assessments at 14 days and 30 days from the date of their first study treatment, and 14 days, 30 days, 3 months and 6 months from the date of their second study treatment. Subjects in the active treatment group will also undergo follow-up assessments at 9 months and 12 months from the date of their second study treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01722461
Study type	Interventional
Source	Merz Pharmaceuticals, LLC
Contact
Status	Terminated
Phase	N/A
Start date	November 2012
Completion date	November 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03627468` - A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis	Phase 3
Completed	`NCT03658616` - Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary Axillary Hyperhidrosis and the Assessment of Long-term Efficacy and Safety of Topical Administration of 1% GPB Cream in Patients With Primary Axillary Hyperhidrosis.	Phase 3
Completed	`NCT02286765` - Ulthera® System for Treating Axillary Hyperhidrosis	N/A
Completed	`NCT04599907` - Evaluation of N-SWEAT Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating	N/A
Completed	`NCT03037788` - Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary Hyperhidrosis	Phase 1
Completed	`NCT05863104` - Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis	Phase 2
Completed	`NCT02823340` - Fractionated Microneedle Radiofrequency for Treatment of Primary Axillary Hyperhidrosis	N/A
Not yet recruiting	`NCT04159610` - Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects With Primary Axillary Hyperhidrosis	Phase 2
Completed	`NCT01799824` - Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis	Phase 2
Completed	`NCT03785587` - A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis	Phase 2
Completed	`NCT03054480` - Fractional Micro-Needle Radiofrequency and I Botulinum Toxin A for Primary Axillary Hyperhidrosis	N/A